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Abstract
Background—Combination antiretroviral (cARV) regimens are recommended for pregnant
women with HIV to prevent perinatal HIV transmission. Safety is a concern for infants who were
HIV-exposed but uninfected (HEU), particularly for neurodevelopmental problems, such as
language delays.
Methods—We studied late language emergence (LLE) in HEU children enrolled in a US-based
prospective cohort study. LLE was defined as a caregiver-reported score ≤ 10th percentile in any
of 4 domains of the MacArthur-Bates Communicative Development Inventory for one-year-olds
and as ≥1 standard deviation below age-specific norms for the Ages and Stages Questionnaire for
two-year-olds. Logistic regression models were used to evaluate associations of in utero cARV
exposure with LLE, adjusting for infant, maternal, and environmental characteristics.
Results—1,129 language assessments were conducted among 792 one- and two-year-olds (50%
male, 62% black, and 37% Hispanic). Overall, 86% had in utero exposure to cARV and 83% to
protease inhibitors. LLE was identified in 26% of one-year-olds and 23% of two-year-olds, with
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higher rates among boys. In adjusted models, LLE was not associated with maternal cARV or
ARV drug classes in either age group. Among cARV-exposed one-year-olds, increased odds of
LLE was observed for those exposed to atazanavir (aOR=1.83, 95% CI=1.10-3.04), particularly
after the first trimester (aOR=3.56, p=0.001), compared to atazanavir-unexposed infants. No
associations of individual ARV drugs with LLE were observed among two-year-olds.
Conclusions—In utero cARV exposure showed little association with LLE, except for a higher
risk of language delay observed in one-year-old infants with atazanavir exposure.
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Pregnancy; HIV-exposed infants; antiretroviral; cohort study; language delay
Early language acquisition appears during the first year as gestures (showing intent to
communicate), rudimentary understanding of spoken language, and first spoken words at
12-18 months, with rapid vocabulary growth from two years onward. Delayed onset of
language can be described as late talking and/or late understanding of spoken language,
relative to age expectations. The term “Late Language Emergence” (LLE) defines a delayed
onset of language as low performance, relative to age norms, for first word use or
understanding, or both, in the general population of young children, controlling for
multilingual exposures1. In the general population, predictors of early gestural
communication include maternal, environmental, and child factors1-3, and are not
necessarily the same as predictors of early verbal productions2, perhaps due to different
neurologic requirements for gestures versus spoken words. Recent studies highlight the vital
importance of the prenatal period on infants’ subsequent development4,5. For example,
maternal alcohol use during pregnancy is known to influence children’s neurodevelopment,
including risk for language impairments6,7.
In a previous study, we found that school age children with perinatal HIV infection (PHIV)
and those HIV-exposed but uninfected (HEU) had a higher risk for language impairments
compared to children without HIV exposure8. The risk for language impairments was higher
for children with concurrent cognitive or hearing impairments, but the PHIV group did not
differ from the HEU group. Among children with PHIV, those with poorly controlled HIV
or with cognitive or hearing impairments had three times the risk for language impairments
compared to those with controlled HIV and those with no cognitive or hearing impairments.
For children born more recently to mothers with HIV, in utero exposure to combination
antiretroviral drugs (cARV) is common9, resulting in very low risk for HIV transmission to
the infant. Increasingly, newer generations of drugs within existing classes of antiretrovirals
(ARV), and newer classes of ARVs are being used as part of these cARV regimens. Among
studies that have been conducted to evaluate neurodevelopmental functioning in children
born to mothers with HIV infection, none have specifically addressed language impairment,
despite the fact that language and hearing impairments may reflect some of the most
sensitive indicators of ARV-associated toxicities10. Hence, as these regimens evolve over
time, it is important to understand whether in utero exposure to cARV, or to particular drugs
in the regimen, increases a child’s risk for language impairment. If so, it is important to
know if the risk is evident early in development given the known benefits of early
intervention10.
A recent study11 of HEU infants ages 9-15 months reported no consistent association of
individual ARVs with any domain of the Bayley Scales of Infant and Toddler Development,
Third Edition (Bailey-III)12, except for the Language domain. One drug, atazanavir, was
associated with lower scores on the Language domain in both primary analyses and in
sensitivity analyses omitting the intermediaries of prematurity and small for gestational age
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(SGA). This study was conducted with the same cohort under investigation here. Further
investigation is needed to determine if the association of atazanavir and early language
acquisition is evident with more detailed measurements of early language acquisition and if
exposure to atazanavir predicts risk of LLE when controlled for other factors, such as
cognitive delay and hearing impairment. Selective impairment of language acquisition in
infancy would help clarify whether language impairment is apparent from onset or if it
reflects a cumulative effect apparent only later in development. Further evidence of an
association with an individual drug in cARV could clarify possible mechanisms of drug
effects early in development. The overall objective of the current study was to evaluate
further the safety of maternal ARV use on language acquisition in the first two years of life,
by considering the association of LLE with cARV, ARV drug classes, and individual ARV
drugs, controlling for other relevant caregiver, environmental, and child factors.
MATERIALS AND METHODS
Participants
This investigation used data collected in the Surveillance Monitoring of ART Toxicities
(SMARTT) study, a prospective cohort study conducted by the Pediatric HIV/AIDS Cohort
Study (PHACS) network at 22 sites in the United States including Puerto Rico. SMARTT is
designed to identify potential ARV-related toxicities, including language impairment,
through an ongoing surveillance system among infants and children who are HEU13. The
study protocol was approved by institutional review boards at participating sites, and written
informed consent was obtained from each child’s parent/legal guardian. Beginning in 2007,
the study recruited two HEU cohorts: the ongoing Dynamic Cohort, which prospectively
enrolled pregnant women and their newborns from week 22 of gestation through 72 hours
after birth, and the Static Cohort (closed to further accrual in 2009), which included children
< 12 years of age at entry who participated in a previous cohort study where data regarding
the mother’s ARV exposures during pregnancy were collected. Children and their mothers
(or caregivers) are seen at annual study visits around the time of the child’s birthday, and
language assessments are conducted at specific ages, beginning at age 12 months. The
sequence of participant eligibility based on the schedule of data collection and availability of
language measures is presented in the Figure.
Language Assessments
We analyzed prospectively-collected language assessments based on caregiver report
obtained by trained neuropsychologists at ages 12 and 24 months. At the 12-month visit, the
MacArthur-Bates Communicative Development Inventory (CDI)14 was administered to
yield age-adjusted, gender-specific, percentile scores in four domains: Phrases Understood,
Vocabulary Comprehension, Word Production, and Total Gestures. Consistent with previous
studies2, LLE was defined as a score ≤ 10th percentile in any of the four domains, and severe
LLE was defined as a score ≤ 5th percentile in at least two domains. A summary score on the
CDI was calculated by summing the percentile scores of the four domains (range 0-396). At
the 24-month visit, the Communication scale of the Ages and Stages Questionnaire (ASQ)
was administered in place of the CDI, due to the time constraints at that study visit. The
assessment consists of six items that ask about following directions, receptive vocabulary,
expressive vocabulary, and imitation/spontaneous production of word combinations. The
summative score is a Total Score (range 0-60). LLE was defined as a Total Score one
standard deviation (SD) or more below the mean, based on age-specific means and SDs
provided in the ASQ manual. Severe LLE was defined as a Total Score below 26.5
regardless of age (approximately two SDs below the mean). Spanish-speaking children
received Spanish versions of the CDI and ASQ.
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Maternal ARV history during pregnancy was collected through medical record review and
from prior studies where PHACS had received permission to obtain participant-level data.
Maternal combination ARV use, or “cARV”, was defined as use of at least three drugs from
at least two different ARV drug classes during pregnancy, whether for treatment of maternal
HIV infection or for prevention of mother-to-child transmission of HIV. ARV drug classes
evaluated for cARV included non-nucleoside reverse transcriptase inhibitors (NNRTIs) and
protease inhibitors (PIs). Exposures to cARV, ARV drug classes, and individual ARV
agents were recorded as any exposure and exposure for each trimester.
Risk factors evaluated for LLE included infant characteristics (age, sex, race, ethnicity,
multilingual exposure, hearing problems [based on hearing screening or caregiver report],
gestational age at birth, birth weight, cognitive delay [based on Bayley-III scores], and
neonatal ARV prophylaxis), caregiver characteristics (marital status, education and income
levels, verbal and nonverbal IQ), maternal substance use during pregnancy (tobacco,
alcohol, illicit drug use), maternal immune status during pregnancy (latest CD4 count,
CD4%, and viral load [VL] prior to labor and delivery and earlier in pregnancy, when
available), and caregiver health limitations (difficulty caring for child, difficulty doing
housework, and positive screen for depression). Demographic characteristics were obtained
at study entry and subsequent visits through chart review, standardized assessments, and
interviews with caregivers. Maternal substance use during pregnancy was based on self-
report, validated in this SMARTT sample via meconium assay15.
Statistical Methods
Demographic and maternal characteristics were summarized by LLE status for 12- and 24-
month old children. Logistic regression models were used to assess the association of LLE
with in utero cARV exposure and by ARV drug class, comparing those exposed versus
unexposed at any time during pregnancy. The regimens during pregnancy were also
classified into one of three categories: cARV with PIs, cARV without PIs, and non-cARV
(which also included a regimen of 3 or more nucleoside reverse transcriptase inhibitors
[NRTIs]). The non-cARV group includes three or more NRTIs, other non-cARV regimens,
and not on ARVs. In order to reduce confounding by indication, analyses of associations
between LLE and individual ARV agents were restricted to infants with in utero cARV
exposure. For agents or drug classes with p-value < 0.10 in adjusted models, further analyses
were conducted based on the time of first reported exposure (first trimester, second/third
trimester, or no exposure).
Potential confounders of the relationship between LLE and in utero ARV exposure were
identified by fitting univariate logistic regression models to evaluate demographic, infant,
and caregiver/maternal factors as predictors of LLE at both 1 and 2 years of age. Variables
with unadjusted p-values <0.20 were considered in a backward selection procedure and
those with p-values < 0.15 were retained to create a ‘core’ model. We did not consider
inclusion of characteristics reflecting concurrent impairment (cognitive delay, hearing
problems) or birth characteristics (preterm birth16-18, SGA) in the core model due to
concerns that they may be on the causal pathway between in utero ARV exposure and
LLE19.
We evaluated the association of in utero ARV exposures with LLE based on the CDI and
ASQ using logistic regression models, adjusting for the core covariates described above. In
addition, we conducted several sensitivity analyses. The first set of sensitivity analyses
included adjustment for birth characteristics (prematurity, SGA), concurrent impairment
(cognitive delay, hearing problems), or both, in addition to the core model covariates, since
these factors may be on the causal pathway. Second, we conducted sensitivity analyses on
the ASQ restricted to children within a narrower age range corresponding to expected visit
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windows (21-27 months) to make sure that the results we saw with the full cohort were
comparable to the results within the intended age range of the ASQ. Additional sensitivity
analyses were conducted to evaluate the potential effect of clinical research site, by fitting
models with a random effect of site to account for within-site correlation in LLE outcomes.
To provide additional power and descriptive information, analyses of the association of
language functioning with in utero ARV exposures were performed using the continuous
CDI summary score for one-year-olds and ASQ Total Score for two-year-olds. A linear
regression model was fit using a robust Generalized Estimating Equation (GEE) approach to
evaluate differences in the mean summary score for those with versus without each ARV
exposure. For both CDI and ASQ, new core models were developed using the modeling
approach described above. Two subscales of the CDI--Word Production and Total
Gestures--were considered separately using the same modeling strategy. All analyses were
based on data submitted as of April 1, 2011 and were conducted using SAS Version 9.2
(SAS Institute Inc., Cary, NC). Two-sided p-values < 0.05 were considered statistically
significant. Because this was a safety study, there was no correction for multiple
comparisons in order to minimize the Type II error rate (eg, the probability of not detecting
true associations between ARV exposures and language outcomes). Due to the numerous
ARV exposures evaluated, observed associations will require confirmation in further
studies.
RESULTS
Study Population and Language Functioning
The CDI and ASQ were obtained from groups with similar backgrounds (Table 1). For the
CDI, 51% were female, 70% black, and 33% Hispanic; 71% had annual household income
below $20,000; 98% of caregivers were the infants’ biological mothers and 32% of
caregivers had not graduated from high school. The percent of children from the Dynamic
cohort was higher for those assessed by the CDI (71%) than for the ASQ (51%). Within both
age groups, 43% were exposed to cARV in the first trimester, increasing to 86% by the third
trimester. For the CDI, 12% were exposed in utero to an NNRTI, and 83% to a PI. ARV
exposures were similar for two-year-olds.
Valid data were obtained for 577 children on the CDI at the 12-month visit (age range:
9.0-18.9 months) and for 552 children on the ASQ at the 24-month visit (age range:
20.1-34.2 months) (see Figure). Some children (n=215) in the Static cohort were enrolled
into the study at the 24 month visit and did not have the 12-month CDI assessment; others
(n=240) had not yet reached 24 months of age and had only the 12 month visit. A total of
337 children had both the CDI and ASQ assessments. Mean (standard deviation [SD] and
95% confidence intervals [CI]) percentiles on CDI subtests were: Phrases Understood, 54.1
(27.7, 51.8-56.4); Vocabulary Comprehension, 44.5 (30.0, 42.0-47.0); Word Production,
47.6 (21.3, 45.9-49.3); and Total Gestures, 46.9 (28.3, 44.6-49.2). The mean percentiles
were significantly below the population norms of 50 for the latter three CDI subtests, but
above norms for the Phrases Understood subtest. The mean (SD) summary score was 193.0
(83.9, 186.1-199.9). A total of 149 (26%, 22.3-29.6%) one-year-olds met the criteria for
LLE; 6% (4.1-8.1%) (n=34) were classified with severe LLE. For the 552 ASQ assessments,
the mean (SD) Total Score was 45.3 (15.6, 44.0-46.6). Among these 2-year olds, 128 (23%,
19.7-26.9%) were classified with LLE; 78 (14%, 11.3-17.3%) with severe LLE. Among the
337 children with both CDI and ASQ assessments, the correlations between CDI subtests at
12 months and the ASQ Total Score were as follows (Spearman’s ρ): Phrases Understood
(0.29), Vocabulary Comprehension (0.29), Total Gestures (0.32), Word Production (0.27),
and Summary Score (0.37), all of which were statistically significant.
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Association of LLE with In Utero ARV Exposure and Other Factors
Among 1-year olds, boys had higher odds of LLE (adjusted odds ratio [aOR]=1.54, p=0.03)
than girls (Table 2). Infants whose caregiver had a verbal IQ <85 had over twice the odds of
LLE (aOR=2.10, p=0.003). Other variables associated with higher odds of LLE and retained
in the adjusted model at the 12-month visit were multilingual exposure, combination
neonatal ARV prophylaxis (vs zidovudine alone), and low maternal CD4% prior to labor
and delivery; also retained was maternal VL>400 copies/mL early during pregnancy,
associated with lower odds of LLE. Boys also had higher odds of LLE at the 24-month visit
(aOR=2.00, p=0.002). Low maternal CD4% during pregnancy and caregiver health
problems were associated with increased odds of LLE at 24 months, but infants whose
caregivers reported that poor health limited their daily activities had lower odds of LLE. At
both the 12-month and 24-month visits, there was no association of LLE with cARV or
ARV drug class in either unadjusted or adjusted models (Table 3).
Association of LLE with Exposure to Individual ARVs
Among 1-year old children with in utero cARV exposure, the odds of LLE were increased
for those exposed to atazanavir (aOR=1.83, p=0.02) but the association was not significant
at 24 months (Table 3). There was also an increased odds of LLE associated with saquinavir
exposure at 12 months (aOR=2.74, p=0.03) but at 24 months the effect changed directions
and was not statistically significant (aOR = 0.15, p=0.06). Drug exposure differed for
atazanavir and saquinavir; 21% of 1 year-olds and 19% of 2 year-olds had in utero exposure
to atazanavir compared to only 5% of both age groups for saquinavir. When examining the
timing of atazanavir exposure, there was a threefold increase in odds of LLE associated with
later atazanavir use (first use during the second/third trimester) compared to absence of
atazanavir exposure (aOR=3.56, p=0.001). Among two-year-olds with in utero cARV
exposure, there were no significant associations between LLE and any individual ARV drug
based on either overall exposure (Table 3) or first trimester exposure (data not shown).
Sensitivity Analyses
The association of LLE with atazanavir based on the CDI remained in sensitivity analyses
adjusting for preterm birth and SGA (aOR=1.83, p=0.02) but was attenuated when adjusted
for cognitive delay and hearing problems (aOR=1.67, p=0.06). There was no association of
LLE with first trimester exposure to any individual ARV (data not shown). When ASQ
analyses were restricted to those between 21 and 27 months of age (corresponding to the
visit window for the ASQ; n=485) results were essentially unchanged. In sensitivity analyses
accounting for study site effects on the CDI, we observed weak within-site correlations in
LLE at 1 year (r=0.03) and the associations between LLE and ARV exposures remained
similar in magnitude and significance. The association of atazanavir with LLE remained
significant (aOR=1.86, p=0.04) while the association with saquinavir was no longer
significant (aOR=2.95, p=0.08).
Among 2-year olds with in utero cARV exposure, there were no significant associations
between LLE and any individual ARV based on either any exposure (Table 3) or first
trimester exposure (data not shown).
Association of Language Scores with In Utero ARV Exposure and Other Factors
A summary of GEE linear regression models for the CDI summary score for 1-year olds and
the ASQ Total Score for 2-year olds is shown in Table 4. In both unadjusted models (not
shown) and after adjustment for potential confounders, there was no association of in utero
cARV exposure or ARV class exposure, either at any time during pregnancy or during the
first trimester, on mean scores within either age group. In addition, there was no significant
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difference in mean scores by regimen (cARV with PI vs. cARV without PI vs. non-cARV
regimens, data not shown). Exposure to a cARV regimen without PI was associated with a
marginally higher mean Total Score on the ASQ (6.7 points higher, p=0.07) as compared to
a non-cARV regimen.
In evaluation of separate subscales of the CDI (data not shown), there was a significant
decrease of 7.7 points (p=0.02) for the Total Gestures subscale among 1-year olds exposed
to PIs; this decrease in mean score was observed in those with exposure to PIs later in
pregnancy (second or third trimester) compared to those not exposed to PIs. For the Word
Production subtest, atazanavir exposure was associated with a significantly lower score in
both unadjusted and adjusted models (adjusted mean decrease = 4.9 points, p = 0.04). In
contrast, no association was observed with the Total Gestures subscale for atazanavir or any
other ARV drug. Among cARV-exposed 2-year olds, no significant associations between
individual ARV agents and mean ASQ Total Score were observed after adjustment for other
covariates.
Most of the covariates identified as predictive of LLE in the logistic regression models
(Table 2) were associated with the continuous summary scores (Table 4). Boys had lower
mean language scores than girls and significantly higher odds of LLE. Maternal/caregiver
performance IQ <85 was associated with significantly lower CDI summary scores. Maternal
immune status during pregnancy (low CD4% or detectable VL) was associated with the CDI
summary score and the ASQ Total Score consistent with the logistic regression models,
although the relationship with viral load was counterintuitive (early maternal VL>400
copies/mL was associated with higher mean scores). Limitations in caregiver health,
including fatigue and difficulty caring for the child, were associated with lower mean scores
on the CDI and ASQ and with increased odds of LLE. Maternal alcohol use during
pregnancy was associated with a 21.3 point decrease in mean CDI summary score after
adjustment for other factors but was not a risk factor for LLE within either age group.
DISCUSSION
An earlier study of school age children enrolled in PHACS found that children perinatally
exposed to HIV were at high risk for language impairments (39%), and the risk was similar
for children with and without HIV infection.8 The results of the current study extend the
concern for language delay to HEU infants and toddlers. LLE was identified in 26% of one-
year-olds and in 23% of two-year-olds, prevalence estimates somewhat higher than reported
in previous studies in the general population1,2. Reilly et al2 reported 20% with LLE based
on the CDI at age 2, for a sample of children which included those with multilingual
exposure (6.6%, similar to the 6.8% in this study). Zubrick et al1 reported 13% with LLE on
the ASQ at age 2, excluding children with multilingual exposure.
The associations of LLE with some demographic and maternal characteristics were
generally consistent with previous studies of infants in the general population and of those
enrolled in SMARTT11. Boys had lower language scores and were more likely to be
identified with LLE at both 12 and 24 months of age1,2. Multilingual exposure has been
associated with LLE in 2-year olds2. We observed that lower maternal/caregiver verbal
ability was associated with higher risk of LLE for 1-year old infants, while Feldman et al3
found lower maternal education to be associated with higher scores on the CDI in 1-year
olds and noted similar outcomes in other studies. The apparent discrepancy may be
attributable to different patterns of prediction for the low end of performance versus the full
range of performance in one-year-old infants, or for greater sensitivity of maternal verbal
intellectual functioning as a predictor variable. Although maternal alcohol use was
associated with a decrease in mean CDI score at 12 months, it was not a risk factor for LLE
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within either age group. This may be because adverse effects of maternal alcohol use on
children’s early language acquisition are more likely to occur for children with cognitive
impairment or hearing loss, factors controlled for in the LLE analyses. Maternal ARV use
during pregnancy showed little association with LLE, except that atazanavir was associated
with significantly increased odds of LLE at age 12 months: the effects were more evident for
word productions than for gestural communications. This finding is of particular importance
because use of this medication during pregnancy is increasing (from 2% in 2004 to 20% in
2009)9 and atazanavir is recommended as a preferred ARV drug for use in pregnancy20.
Increased usage of atazanavir is a reflection of its once daily dosing regimen, low pill
burden and lower rate of metabolic, particularly lipid, adverse effects. Further, an
association of in utero atazanavir exposure with lower scores on the Bayley-III12 language
domain was observed in a separate investigation of neurodevelopmental outcomes at age 12
months among 374 infants from the same cohort studied here11. This association should be
examined in other cohorts of HEU infants.
Atazanavir crosses the placenta at an estimated ratio of 20%21. In pregnant women, as in
non-pregnant adults and children, atazanavir (usually in combination with boosting
ritonavir) is commonly associated with elevated serum unconjugated bilirubin22. Normally,
fetal unconjugated bilirubin crosses the placenta to maternal circulation and then is
conjugated and eliminated by the mother’s liver. However, atazanavir-related impairment of
maternal bilirubin conjugation and elevated maternal unconjugated bilirubin levels may
result in higher levels of fetal unconjugated bilirubin levels through much of the latter half
of pregnancy. Neonatal hyperbilirubinemia at varying levels has been associated with risk of
developmental delay in multiple domains, including language23-25. Neurodevelopmental
problems associated with neonatal hyperbilirubinemia in some of these studies include
milder and variable deficits (unlike classic kernicterus) and may be detected in the first year
of life but often are not in evidence at older ages. Fetal and neonatal elevations in bilirubin
associated with maternal atazanavir use20 are lower than the extreme neonatal
hyperbilirubinemia linked to neurologic injury. Neither maternal nor infant bilirubin
measurements were collected in our study. It is possible that chronic fetal exposure to milder
elevations of bilirubin during the second and third trimesters could result in subtle
neurotoxicity detected later as LLE in these language evaluations. This is further supported
by data from animal studies of developing neurons suggesting potential neurotoxicity at
much lower bilirubin levels,26 mediated, in part, through mitochondrial toxicity27. These
mechanistic hypotheses should be tested.
The absence of association of atazanavir exposure with LLE at 24 months of age is
reassuring, suggesting that the effect is transient, mild or compensated with ongoing
development. In our sample, among 83 one-year-olds with LLE and available for follow-up
assessment at two years, 34 (41%) still had LLE (data not shown). Some of those with
resolution of LLE may have improved language functioning due to receipt of early
intervention services, which increased from 6% to 10% between ages one and two years in
our cohort. An alternative explanation is that the ASQ is not as sensitive as the CDI for
detecting associations with individual ARV exposures, a limitation of our study protocol.
The CDI assesses four domains, and multiple items on each domain, whereas the ASQ
provided a total score from six items; the greater amount of information from the CDI could
result in greater variation in the individual scores thereby increasing sensitivity as compared
to the ASQ. Longer-term language outcomes in this cohort and investigation of associations
of atazanavir exposure with language, hearing, and other developmental outcomes in other
cohorts will be essential.
Our data suggest careful clinical screening for LLE in infants who are HEU in the first two
years of life. As new ARV agents are approved and become more widely used, in
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combination with NRTIs or other regimens, continued evaluation of language functioning
and other neurodevelopmental outcomes are warranted for ensuring the safety of treatments
for pregnant women with HIV.
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Table 1
Child and Maternal Characteristics of HIV-exposed uninfected SMARTT Study Infants
by Late Language Emergence (LLE) at the 12-Month and 24-Month Visit
Characteristic
LLE on the CDI
at 12-month visit










Infant Demographic and Birth Characteristics
 Age at assessment (in months), Mean (SD) 12.8 (1.5) 13.0 (1.5) 24.3 (1.8) 25.1 (1.8)
 Male sex 84 (56%) 200 (47%) 78 (61%) 197 (46%)
 Black race 93 (69%) 283 (70%) 84 (69%) 269 (68%)
 Latino/Hispanic ethnicity 53 (36%) 81 (19%) 43 (34%) 142 (34%)
 Multilingual exposure 39 (26%) 78 (18%) 40 (31%) 106 (25%)
 Gestational age <37 weeks 53 (36%) 81 (19%) 40 (31%) 91 (22%)
 Small for gestational age 18 (12%) 31 (7%) 19 (15%) 32 (8%)
 Cognitive delay 18 (15%) 10 (3%) 11 (15%) 6 (3%)
 Hearing problems 18 (12%) 15 (4%) 21 (16%) 13 (3%)
 Combination neonatal prophylaxis (vs.
zidovudine alone)
10 (7%) 10 (2%) 4 (3%) 12 (3%)
Caregiver Characteristics
 Household income <$20,000 107 (74%) 295 (70%) 91 (72%) 306 (73%)
 Lack of high school education (or
equivalent)
55 (37%) 128 (30%) 45 (35%) 135 (32%)
 Low verbal IQ (<85) 60 (57%) 129 (41%) 46 (49%) 143 (49%)
 Performance IQ (<85) 41 (39%) 95(30%) 39(42%) 99(34%)
 Health problems 133 (90%) 363 (87%) 116 (95%) 371 (90%)
 Too tired for activities of daily living 43 (29%) 113 (27%) 47 (39%) 133 (32%)
 Difficulty caring for child 26 (18%) 27 (11%) 22 (18%) 71 (17%)
 Cannot do other activity* 8 (5%) 23 (5%) 4 (3%) 32 (8%)
Maternal Exposures/Health Characteristics During Pregnancy
 Earliest maternal VL >400 copies/mL 83 (58%) 275 (66%) 76 (61%) 261 (62%)
 Latest maternal VL >400 copies/mL 29 (20%) 73 (17%) 25 (20%) 73 (17%)
 Earliest maternal CD4% < 25 59 (47%) 154 (40%) 52 (47%) 150 (40%)
 Latest maternal CD4% < 25 52 (39%) 122 (30%) 41 (34%) 109 (27%)
 Tobacco use 29 (20%) 73 (18%) 18 (16%) 72 (18%)
 Alcohol use 15 (10%) 41 (10%) 8 (7%) 31 (8%)
 Illicit drug use 8 (6%) 33 (8%) 9 (8%) 23 (6%)
VL=viral load
LLE=Late Language Emergence
CDI= Communicative Development Inventory
ASQ=Ages and Stages Questionnaire
For the CDI: 37 were missing data on race; 2 on ethnicity; 2 on multilingual exposure. Four were missing gestational age; 116 were missing
information on verbal IQ and 156 on performance IQ; 1 on hearing status; and 2 on neonatal prophylaxis. Twelve were missing household income;
154 caregivers did not have a verbal IQ; and 11 caregivers were missing all health status variables. Fourteen mothers did not have a VL on record
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during pregnancy, 70 did not have a measure for early CD4%, 32 were missing CD4% before delivery, and 11 were missing alcohol, tobacco, and
drug exposures during pregnancy.
For the ASQ: 27 were missing data on race; 2 on ethnicity; 2 on multilingual exposure. Three were missing gestational age; 193 were missing
information on verbal IQ and 169 on performance IQ; and 10 on neonatal prophylaxis. Six were missing household income; 168 caregivers did not
have a verbal IQ; and 16 caregivers were missing all health status variables. Nine mothers did not have a VL on record during pregnancy, 70 did
not have a measure for early CD4%, 31 were missing CD4% before delivery, and 29 were missing alcohol, tobacco, and drug exposures during
pregnancy.
*
Other activity refers to all non-work and non-housework activities.
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